KOSDAQBiotech & Pharma0010V0

JPI Healthcare

₩6,370▼ 7.55%2026-11-18 close
Market Cap
₩32.5B
Turnover
₩2.2B
Volume
290K
Shares out.
5.1M
PER
8.7×
PBR
0.6×
EPS
₩881
Dividend Yield
3.27%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩250 per share · Prices as of the 2026-11-18 close

01

Report overview

Global Grid Leader Faces a 2026 Earnings Slowdown

JPI Healthcare holds a leading global position in X-ray grids, but its operating profit fell sharply in 3Q26 and net income attributable to controlling shareholders turned into a loss, weakening its earnings trend.

  1. 1

    Operating profit rose 23.4% to KRW 4.86 billion in 2025 and the operating margin reached 10.0%, while net income attributable to controlling shareholders fell 12.9% to KRW 5.26 billion.

  2. 2

    3Q26 revenue fell 12.3% year on year to KRW 10.4 billion, operating profit dropped 79.6% to KRW 135 million, and the company posted a net loss of KRW 1.32 billion attributable to controlling shareholders.

  3. 3

    Press reports put its global grid market share at around 40%, and more than 80% of revenue comes from overseas, so exchange-rate moves feed directly into reported profit.

  4. 4

    The debt ratio fell from 59.2% in 2024 to 30.7% in 2025, and a KRW 1 billion treasury share purchase trust was completed in August 2026.

  5. 5

    The next checkpoints are the 2026 full-year preliminary results, the non-operating income and expense breakdown in the 2026 annual report, and whether revenue recovers in 1Q27.

02

Business structure

JPI Healthcare is a digital X-ray imaging solutions company founded in 1980, and its core business is the X-ray grid, a component that removes scatter radiation to sharpen images. The company started as Chungwon Precision Industry, changed its name to JPI Healthcare in 2010, and listed on KOSDAQ in August 2025.

Press reports put its global grid market share at around 40% as of 2025. The revenue mix varies by period in press reports: grids were 45.8%, imaging devices 10.4% and trading goods 43.8% in 3Q25, while grids were 72%, trading and other 21% and imaging devices 7% based on 2Q26 revenue.

Because the two snapshots differ in timing and classification, they are hard to read as a single trend. Grids account for more than 60% of sales and more than 80% of revenue comes from overseas.

Key customers are global imaging equipment makers including GE HealthCare, Siemens Healthineers and Philips, to which the grid components are supplied. In imaging devices, the DTS system StriXion and the mobile CT unit DeteCT are the main products.

Production sites are in Ansan and Siheung, Gyeonggi, and the company emphasizes its mass-production experience with carbon-material grids as a strength.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩11.9B₩700M5.6%
2025Q4₩12.3B₩1.4B11.6%
2026Q1₩10.8B₩500M4.3%
2026Q2₩12B₩2.1B18.0%
2026Q3₩10.4B₩100M1.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2024₩45.1B₩3.9B₩6B8.7%14.6%59.2%
2025₩48.5B₩4.9B₩5.3B10.0%8.3%30.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

On a DART-filed annual basis, revenue rose from KRW 45.1 billion in 2024 to KRW 48.5 billion in 2025, up 7.6% year on year. Operating profit increased from KRW 3.94 billion to KRW 4.86 billion, up 23.4%, and the operating margin widened from 8.7% to 10.0%.

Net income attributable to controlling shareholders fell from KRW 6.04 billion to KRW 5.26 billion, down 12.9%, while net income including non-controlling interests moved from KRW 5.55 billion to KRW 4.84 billion. Operating profit rose while the bottom line fell, which points to non-operating items.

When it announced preliminary 2025 results in February 2026, the company said that its high export exposure led to foreign-exchange losses in period-end revaluation, and that currency effects weighed heavily on finance and other income.

It attributed the fourth-quarter operating slowdown to year-end items such as inventory provisions. The balance sheet improved: the debt ratio dropped from 59.2% to 30.7%, with total liabilities of KRW 19.3 billion and total equity of KRW 63.1 billion at end-2025.

Operating cash flow fell from KRW 3.9 billion to KRW 3.22 billion. Quarterly results swing more widely.

Revenue was KRW 11.9 billion in 3Q25, rose 3.6% to KRW 12.3 billion in 4Q25, fell 12.5% to KRW 10.8 billion in 1Q26, rebounded 11.2% to KRW 12 billion in 2Q26, and dropped 12.9% to KRW 10.4 billion in 3Q26, down 12.3% year on year.

Operating profit was KRW 660 million in 3Q25, KRW 1.42 billion in 4Q25, KRW 458 million in 1Q26, KRW 2.15 billion in 2Q26 and KRW 135 million in 3Q26, which was down 79.6% year on year.

Net income attributable to controlling shareholders rose from KRW 1.25 billion in 3Q25 to KRW 1.72 billion in 4Q25, KRW 1.74 billion in 1Q26 and KRW 2.32 billion in 2Q26, then turned into a net loss of KRW 1.32 billion in 3Q26. The sum over the last four quarters (4Q25 to 3Q26) is KRW 4.47 billion.

A press report citing the quarterly filing put January-September 2026 revenue at about KRW 33.1 billion, down 8.5% year on year.

05

Industry analysis

The grid market is a component market tied to demand for X-ray imaging equipment. When hospitals replace or add equipment, grid orders tend to move with it, and when equipment investment slows, component demand weakens.

Behind the view that the company holds a leading position are its carbon-material grids and its experience in mass-producing high-specification grids. Press reports describe carbon grids as lighter and more radiation-transparent than aluminum grids, placing them in a premium product class.

On competition, press reports say the company overtook Japanese and European makers to reach the top spot in grids. In 2H25, brokerage views argued that wider adoption of next-generation imaging equipment and full-scale mass production of higher-value grids would support 2026 earnings.

However, January-September 2026 revenue fell year on year, so the outlook and actual trend have diverged. Public data that place the industry in its equipment investment cycle are limited, so it is more practical to read company commentary alongside the quarterly trend.

Because the company sells to large imaging equipment makers, changes in customer shipments and order terms can flow into its results quickly. Whether customer equipment shipments recover remains the most direct signal for grid demand.

06

Outlook

The company outlined three medium-term priorities when it listed: expanding share in precision medical imaging, upgrading high-value specialty grids, and building cloud-based generative AI solutions. Concrete capacity plans and revenue targets should be gauged from figures in periodic reports and IR materials.

A disclosure dated August 31, 2026 showed that a KRW 1 billion treasury share purchase trust was terminated, with 113,621 common shares acquired, equal to 2.23% of total issued shares. The 2025 fiscal-year cash dividend on common shares was decided by the board in February 2026.

Brokerage views pointed to wider adoption of next-generation equipment and high-value grid production as drivers of 2026 earnings. However, both operating profit and net income attributable to controlling shareholders worsened from the prior quarter in 3Q26.

The next checkpoint is 4Q26 and full-year 2026 preliminary results. The 2025 full-year preliminary results were announced through the financial regulator's electronic disclosure system on February 23, 2026, so the 2026 full-year preliminary results could similarly come in late February 2027.

At that point, the key question is whether the full-year operating margin holds near the 10.0% level of 2025. The 2026 annual report is due by the end of March 2027, and it will show the grid and imaging device revenue mix and the scale of foreign-exchange gains and losses.

07

Valuation

PER
8.7×
PBR
0.6×
ROE
7.1%
EPS
₩881
BPS
₩12,622
Dividend per share
₩250

Valuation is more about earnings scale and asset structure than about the share price level.

The sum of net income attributable to controlling shareholders over the last four quarters was KRW 4.47 billion, a small earnings base, so earnings-based multiples can move sharply when profit changes even at a similar share price.

The price-to-book ratio is below 1x, which means the shares trade at a discount to book value. Against total equity of KRW 63.1 billion and equity attributable to controlling shareholders of KRW 63.5 billion at end-2025, the share price sits at a low level relative to asset value.

However, net income attributable to controlling shareholders fell in 2025 and turned into a net loss in 3Q26, so earnings-based multiples can be read very differently depending on profit recovery.

A cash dividend was decided for the 2025 fiscal year, but press reports in February 2026 pointed out that the largest shareholder's family holds a large stake, so the benefit concentrates among a few holders.

The treasury share purchase trust was completed in August 2026, which is a concrete step in shareholder returns. The degree of discount depends on whether earnings recover, so the next annual report's profit level will serve as the reference point.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Leading global grid position

Press reports put its global grid share at around 40%, and the company is described as having mass-production experience with carbon-material grids. It supplies global imaging equipment makers including GE HealthCare, Siemens Healthineers and Philips. If demand for high-specification grids grows, component technology could underpin its results.

Profitability gains and a stronger balance sheet in 2025

Operating profit rose 23.4% in 2025 and the operating margin widened from 8.7% to 10.0%. The debt ratio fell from 59.2% to 30.7%. The year showed operating-level profitability gains.

Shareholder return steps

A disclosure dated August 31, 2026 showed that a KRW 1 billion treasury share purchase trust was terminated, with acquired shares equal to 2.23% of total issued shares. The 2025 fiscal-year cash dividend was also decided by the board in February 2026. Shareholder return steps are continuing even with a small earnings base.

09

Bear factors

Slowing quarterly results in 2026

3Q26 revenue fell 12.3% year on year and operating profit dropped 79.6%. A press report citing the quarterly filing also says January-September 2026 cumulative revenue declined year on year. Net income attributable to controlling shareholders turned into a KRW 1.32 billion net loss in 3Q26.

Dependence on exchange rates and overseas sales

More than 80% of revenue comes from overseas, and foreign-exchange losses from period-end revaluation were cited as a reason for the 2025 decline in net income. The company said currency effects weighed heavily on finance and other income even as operating profit rose. Swings in exchange rates can move non-operating results and change how earnings look.

Quarterly volatility and a gap with brokerage views

Revenue fell 12.5% in 1Q26, rose 11.2% in 2Q26 and fell 12.9% again in 3Q26. Brokerage views in late 2025 expected 2026 earnings to be solid, yet cumulative revenue for 2026 declined. A wider gap between outlook and actual trend is a bearish factor.

10

Risk factors

Currency risk

With high export exposure, exchange rates flow directly into period-end revaluation and finance income. The company said foreign-exchange losses weighed on 2025 net income. Depending on the direction of currency moves, the gap between operating profit and net income could widen.

Customer concentration and order volatility

Grids are components supplied to large imaging equipment makers such as GE HealthCare, Siemens Healthineers and Philips. When customers change shipments or order terms, quarterly revenue can move quickly. The swings in 2026 quarterly revenue reflect this structure.

Small-cap liquidity and ownership concentration

As a small-cap stock, trading volume and share price volatility can be large. The largest shareholder, CEO Kim Jin-kook, committed to a two-year-and-six-month lock-up, and the stake including related parties exceeds 30%.

With concentrated ownership, the effects of dividends and share transfers on minority shareholders also need attention.

11

What to watch next

  1. Late February 2027 (typical timing)

    The 2026 full-year preliminary results will show whether 4Q26 operating profit and the annual operating margin hold near the 10.0% level of 2025. Last year's preliminary results were disclosed through the financial regulator's electronic system on February 23, 2026.

  2. End of March 2027 (statutory deadline)

    The 2026 annual report will show segment revenue, the scale of foreign-exchange gains and losses, non-operating items and customer mix. It will indicate whether the 3Q26 net loss carried through to the full year.

  3. March 2027 (typical annual general meeting timing)

    The timing at which the 2026 fiscal-year dividend decision is confirmed. It will also show whether the distribution remains concentrated among the largest shareholder's family.

  4. By May 15, 2027 (statutory deadline)

    The statutory deadline for the 1Q27 quarterly report. It will show whether revenue recovers from the KRW 10.8 billion in 1Q26 and whether operating profit exceeds the KRW 458 million level of that quarter.

12

Overall view

JPI Healthcare holds a leading global position in X-ray grid components, and its market share and experience with carbon-material grid mass production are its main strengths. In 2025, operating profit and the operating margin improved and the debt ratio declined.

In 2026, however, quarterly revenue has swung up and down, and in 3Q26 operating profit fell 79.6% and the company posted a net loss attributable to controlling shareholders. Because exchange rates weigh heavily on period-end revaluation and finance income, earnings volatility is larger.

On shareholder returns, a treasury share trust was completed and a cash dividend was decided, but press reports noted that the benefits are concentrated among the largest shareholder's family. The brokerage outlook for 2026 earnings improvement also diverged from the actual quarterly trend.

The next checkpoints are the 2026 full-year preliminary results, the non-operating breakdown in the annual report, and whether revenue recovers in 1Q27.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. jpi-korea.com
  2. jobkorea.co.kr
  3. saramin.co.kr
  4. incruit.com
  5. jobkorea.co.kr
  6. comp.fnguide.com
  7. jobplanet.co.kr
  8. news.bizwatch.co.kr
  9. pharm.edaily.co.kr
  10. jpi-korea.com
  11. m.news.nate.com
  12. vegannews.co.kr
  13. kpinfo.kr
  14. jlab.incruit.com
  15. butler.works
  16. dailyinvest.kr
  17. datatooza.com
  18. eugenefn.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis